A rare cause of chronic mesenteric ischemia from fibromuscular dysplasia: a case report

Viplove Senadhi

Abstract

Introduction: Chronic mesenteric ischemia is a condition that is classically associated with significant atherosclerosis of the abdominal arteries, causing postprandial abdominal pain out of proportion to physical examination. The abdominal pain is exacerbated after meals due to the shunting of blood away from the intestines to the stomach, causing relative ischemia. More than 95% of chronic mesenteric ischemia cases are due to atherosclerosis. We report the first known case of chronic mesenteric ischemia from fibromuscular dysplasia. To the best of our knowledge, this is also the first known case in the literature where postprandial abdominal pain was the presenting symptom of fibromuscular dysplasia.

Case presentation: A 44-year-old Caucasian woman with a history of hypertension and preeclampsia, who had taken oral contraceptive pills for 15 years, presented with intractable, colicky abdominal pain of two weeks duration. This abdominal pain worsened with oral intake. It was also associated with diarrhea and vomiting. Physical examination revealed stage III hypertension out of proportion to her risk factors and diffuse abdominal pain without peritoneal signs. An abdominal computed tomography scan, completed in the emergency room, revealed nonspecific colitis. Laboratory work revealed leukocytosis with a left shift, an erythrocyte sedimentation rate of 79 and a C-reactive protein level of 100. She was started on intravenous flagyl and intravenous ciprofloxacin. However, all microbial cultures were negative including three cultures for clostridium difficile. Urine analysis revealed nephritic range proteinuria. The laboratory profile was within normal limits for perinuclear-anti-neutrophil cytoplasmic antibody, cytoplasmic-anti-neutrophil cytoplasmic antibody, anti-saccharomyces cerevisiae antibody, antinuclear antibody test, celiac profile, lactate, carbohydrate antigen-125 and thyroid stimulating hormone. A colonoscopy was completed, which revealed diffuse colonic lymphoid reactive hyperplasia. A small bowel series was negative for any inflammation. An indium scan, pan-computed tomography scan and transvaginal ultrasound were also negative. Magnetic resonance angiography of her abdomen revealed proximal superior mesenteric artery stenosis, which was confirmed by computed tomography angiogram findings of severe proximal and distal superior mesenteric artery stenosis, consistent with the appearance of fibromuscular dysplasia on angiography in the absence of vasculitis or atherosclerotic disease. The patient’s superior mesenteric artery stenosis was subsequently angioplastied suboptimally and had to be stented with an Angioplus stent. One month after she was admitted, her abdominal pain and tolerance to oral feeds improved tremendously.

Conclusion: Fibromuscular dysplasia most commonly presents with renal artery stenosis, which rarely causes abdominal pain. This case illustrates how fibromuscular dysplasia can present as a rare cause of chronic mesenteric ischemia, similar to chronic mesenteric ischemia from atherosclerosis.
Introduction

Chronic mesenteric ischemia is a condition classically associated with significant atherosclerosis of the abdominal arteries causing postprandial abdominal pain out of proportion to physical examination [1]. The abdominal pain is exacerbated after meals due to the shunting of blood away from the intestines to the stomach causing relative ischemia. More than 95% of chronic mesenteric ischemia cases are due to atherosclerosis [1]. We report the first known case of chronic mesenteric ischemia from fibromuscular dysplasia. This is the first known case in the literature where the presenting symptom of fibromuscular dysplasia was postprandial abdominal pain.

Case presentation

A 44-year-old Caucasian woman with a history of hypertension and preeclampsia who had taken oral contraceptive pills (OCPs) for 15 years, presented with intractable, colicky abdominal pain of two weeks duration. This abdominal pain worsened with oral intake. It was also associated with diarrhea and vomiting. The diarrhea was watery at times and was confirmed to be hemoccult positive. Her vomiting was non-bilious and was consistent with gastric contents, with a negative gastrocct test. No abnormal findings were found on physical examination except for stage III hypertension. Her body mass index was 16.1 with a left shift (91% polymorphonuclear neutrophils), an erythrocyte sedimentation rate (ESR) of 79, and a C-reactive protein level (CRP) of 100. An abdominal computed tomography (CT) scan completed in the emergency room revealed nonspecific colitis. The patient was taken to angiography which revealed near complete full length occlusion of the SMA and several branches including mild renal artery stenosis (Figure 3). The angiography findings were consistent with atypical fibromuscular dysplasia with a medial pattern. The suspicion was high given the lack of atherosclerotic lesions, absence of hyperlipidemia, negative vasculitis workup, and pattern of occlusions seen on angiography. The patient’s severe SMA stenosis subsequently underwent suboptimal angioplasty, which warranted a 6 × 15 Palmaz Blue Angioplus stent (Figures 4, 5, 6). Her symptoms improved tremendously, in that her abdominal pain subsided and she had an improved tolerance to oral feeds.

Discussion

Due to the findings of severe proximal or distal SMA stenosis, the diagnosis of subacute mesenteric ischemia versus chronic mesenteric ischemia was considered. Non-occlusive mesenteric ischemia was ruled out based on the lack of hypotension and the patient’s overall clinical history. Colonic ischemia, which is the most common form of ischemic vascular compromise, was ruled out based on the colonic biopsy and clinical history [2]. This prompted the differential diagnoses of fibromuscular dysplasia versus a hypercoagulable state causing mesenteric vascular thrombosis, or a chronic atherosclerotic process with an acute thrombosis. The patient did not have any risk factors for arterial embolic disease, such as atrial fibrillation, valvular or heart surgery or cardiac mural thrombosis.

The patient’s age and risk factors made the diagnosis of chronic mesenteric ischemia from atherosclerosis very unlikely. She had no known history of peripheral vascular disease or an equivalent, which are high risk factors for atherosclerosis [1]. Her body mass index was...
19.2 and she was considered in great health prior to this hospitalization. Additionally, the patient did not have a history of hyperlipidemia or smoking, known risk factors for atherosclerotic mesenteric ischemia. Also, most patients with chronic mesenteric ischemia from atherosclerosis are over the age of 60 [1]. Thus, atherosclerotic chronic mesenteric ischemia was thought to be highly unlikely.

The consideration for venous thrombosis was then evaluated. The patient was anticoagulated with IV heparin, which could not be continued secondary to bleeding. The hypercoagulable workup done in the absence of anticoagulation, including antithrombin-3 antigen level, lupus anticoagulant, beta II glycoprotein antibody, cardiolipin antibody, protein C/S and homocystinuria, showed negative results. We ruled out venous thrombosis from antithrombin-3 deficiency and all other hypercoagulable states. Additionally, isolated abdominal vein thrombosis in the absence of deep venous thrombosis, pulmonary embolus and stroke made a hypercoagulable venous state very unlikely. It was agreed by vascular surgery from the MRA and CT angiography findings that the patient did indeed have fibromuscular dysplasia causing superior mesenteric artery stenosis as well as renal artery stenosis, especially considering the absence of hyperlipidemia and inflammation (Figures 1 and 2). The patient was taken to angiography where she underwent a suboptimal angioplasty of her SMA, which
was followed up with an immediate $6 \times 15$ Palmaz Blue Angioplus stent (Figure 3, figure 4, figure 5 and figure 6). Heparin was restarted after completing the hypercoagulable work up and the patient’s clinical status improved with anticoagulation and clopidogrel bisulfate (Plavix). After more than a month of hospitalization, she was discharged with clopidogrel bisulfate alone for her abdominal stent. She was tolerating oral feeds and is back to her baseline lifestyle at a one-year follow-up. Several times during her care, she was advised to have significant abdominal surgery. However, due to the recognition of her diagnosis, our team felt confident with her management and advised a conservative approach. Overall, she did very well and returned to a normal lifestyle, while avoiding significant abdominal surgery.

Chronic mesenteric ischemia from atherosclerosis is ideally managed with surgical correction via transaortic endarterectomy, external iliac retrograde bypass or anterograde bypass [3-9]. However, there are studies that state stenting has been equivalent with respect to short-term and long-term outcomes [8,9]. In our case, distal small vessel disease of the SMA made surgery less favorable [10,11]. Warfarin and nitrates are typically used in the treatment of chronic mesenteric ischemia from atherosclerosis [4]. Our patient was managed with an
Angioplus stent with clopidogrel bisulfate alone to prevent stent thrombosis.

Fibromuscular dysplasia is a nonatherosclerotic, non-inflammatory condition that leads to the narrowing of medium sized arteries. Fibromuscular dysplasia classically affects the renal arteries (63% to 89%) and presents most commonly with secondary hypertension [12]. The least common sites of involvement are the mesenteric (9%) and iliac (5%) arteries. Fibromuscular dysplasia in atypical sites such as the mesenteric arteries may go undiagnosed.

![Image: Figure 3 Angiogram showing superior mesenteric artery (SMA) stenosis.](http://www.jmedicalcasereports.com/content/4/1/373)
unless the stenosis is severe, as in our patient [1]. The classic diagnosis of fibromuscular dysplasia is made on angiography as a 'string of beads appearance’. However, this only represents 60% to 70% of fibromuscular dysplasia cases [12]. Atypical fibromuscular dysplasia, defined as not representing the classic appearance, is a much more difficult diagnosis [13,14]. Atypical fibromuscular dysplasia is usually diagnosed on the basis of strong clinical suspicion without signs of atherosclerotic disease or vasculitis induced inflammation, such as in our
However, acute infarction of the involved arteries can mislead physicians, as it will raise inflammatory markers. In atypical fibromuscular dysplasia, the angiographic appearance can appear very similar to atherosclerotic lesions as there are smooth concentric lesions [12]. However, subtle distinctions can be made as atherosclerosis is a diffuse process and does not occur in the absence of other systemic arterial involvement. Atypical fibromuscular dysplasia is much more likely in the appropriate clinical context, such as in our patient.

**Conclusion**

Fibromuscular dysplasia most commonly presents with renal artery stenosis, which rarely causes abdominal pain. This case illustrates how fibromuscular dysplasia can present with postprandial abdominal pain and as a rare cause of chronic mesenteric ischemia, similar to chronic mesenteric ischemia from atherosclerosis. Additionally, this case also illustrates the clinical and angiographic presentation of atypical fibromuscular dysplasia, which does not present with the classic 'string of beads' appearance on angiography. The management of
Fibromuscular dysplasia induced chronic mesenteric ischemia is similar to the management of atherosclerotic chronic mesenteric ischemia based on this case. However, surgical revascularization is not absolutely necessary in fibromuscular dysplasia induced chronic mesenteric ischemia and abdominal artery stents with angioplasty can be placed with successful patient outcomes. Lastly, this case illustrates that angioplasty and Angiplus stents can be used with clopidogrel bisulfate without warfarin or vasodilators, such as nitrates, in chronic mesenteric ischemia secondary to fibromuscular dysplasia.

Consent
Written consent was obtained from the patient for publication of the case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of the journal.

Abbreviations
ANA: antinuclear antibody test; ASCA: anti-saccharomyces cerevisiae antibody; CA-125: cancer antigen 125; C-ANCA: cytoplasmic-anti-neutrophil cytoplasmic antibody; CRP: C-reactive protein; CT: computed tomography; ESR: erythrocyte sedimentation rate; IBD: inflammatory bowel disease; IV: intravenous; MRA: magnetic resonance angiography; OCP: oral contraceptive pills; P-ANCA: perinuclear-anti-neutrophil cytoplasmic antibody; SMA: superior mesenteric artery.
mesenteric artery; TSH: thyroid stimulating hormone; UA: urinalysis; WBC: white blood cell count.

Acknowledgements
I would like to give special thanks to Dr Peter Mackrell in the Department of Vascular Surgery and Dr Harry Kaplan in the Department of Internal Medicine for their contributions in the patient’s care. Their dedication to improving the standard of patient care and advocating for our patient resulted in a wonderful outcome for her.

Authors’ contributions
VS was integral in the management of the patient, carried out the patient’s medical care to the point of diagnosis/treatment, performed the literature review and wrote the manuscript.

Competing interests
The author declares that they have no competing interests.

Received: 29 January 2010 Accepted: 19 November 2010 Published: 19 November 2010

References
1. Moawad J, Gewertz BL: Chronic mesenteric ischemia. Clinical presentation and diagnosis. Surg Clin North Am 1997, 77:357-369.
2. Cappell MS: Intestinal (mesenteric) vasculopathy. I. Acute superior mesenteric arteriopathy and venopathy. Gastroenterol Clin N America 1998, 27:783-825, vi.
3. Chahid T, Alfiidja AT, Baird M, Ravel A, Gacrer JM, Boyer L: Endovascular treatment of chronic mesenteric ischemia: results in 14 patients. Cardiovascular Interventional Radiol 2004, 21:637-642.
4. Chang JB, Stein TA: Mesenteric ischemia: acute and chronic. Ann Vasc Surg 2003, 17:323-328.
5. English WP, Pearce JD, Craven TE, Edwards MS, Geany RL, Plonk GW, Hansen J: Chronic visceral ischemia: symptom-free survival after open surgical repair. Vasc Endovascular Surg 2004, 38:493-503.
6. Geroulakos G, Tober JC, Anderson L, Smead WL: Antegrade visceral revascularisation via a thoracoabdominal approach for chronic mesenteric ischemia. Eur J Vasc Endovasc Surg 1999, 17:56-59.
7. Hung KH, Lee CT, Lam KK, et al: Ischemic bowel disease in chronic dialysis patients. Chang Keng I Hsueh Tsa Chih 1999, 22:82-87.
8. Kazmers A: Operative management of chronic mesenteric ischemia. Ann Vasc Surg 1998, 12:99-308.
9. Kihara TK, Blake J, Anderson KM, Freidman DB, Atnp RG: Risk factors and outcomes following revascularization for chronic mesenteric ischemia. Ann Vasc Surg 1999, 13:37-44.
10. Lauenstein TC, Aja W, Narin B, Gohde SC, Kroger D, Debatin JF, Ruhm SG: MR imaging of apparent small-bowel perfusion for diagnosing mesenteric ischemia: feasibility study. Radiology 2005, 234:569-575.
11. Mateo RB, O'Hara PJ, Hertzer NR, Mascha EJ, Beven EG, Krajewski LP: Elective surgical treatment of symptomatic chronic mesenteric occlusive disease: early results and late outcomes. J Vasc Surg 1999, 29:821-831, discussion 832.
12. Luscher TF, Lie JT, Stanson AW, Houser OW, Hollier LH, Sheps SG: Arterial fibromuscular dysplasia. Mayo Clin Proc 1987, 62:951-962.
13. den Butter G, van Rokel JH, Arts JC: Arterial fibromuscular dysplasia: rapid progression complicated by rupture of a visceral aneurysm into the gastrointestinal tract. J Vasc Surg 1988, 7:449-453.
14. Begelman SM, Olin JW: Fibromuscular dysplasia. Curr Opinions Rheumatol 2000, 12:41-47.

doi:10.1186/1752-1947-4-373
Cite this article as: Senadhi: A rare case of chronic mesenteric ischemia from fibromuscular dysplasia: a case report. Journal of Medical Case Reports 2010 4:373.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit